ImmuNext, Inc.
8Patents
8Active
8Granted
44Portfolio score
Filing activity: Dec 7, 2015 → Nov 23, 2020
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US10370455B2 | Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists | Chemistry; Metallurgy | 18 | Active |
| US10874738B2 | Anti-CD154 antibody having improved binding, functional and safety characteristics | Physics | 1 | Active |
| US11596689B2 | Methods of immunosuppression comprising administering an anti-CD154 antibody | Physics | 0 | Active |
| US11603402B2 | Anti-human vista antibodies and use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11603403B2 | Anti-human vista antibodies and use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11525000B2 | Anti-human VISTA antibodies and use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US12139532B2 | Anti-human vista antibodies and use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
| US11649283B2 | Anti-human vista antibodies and use thereof | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.